Heron Therapeutics Inc [HRTX] stock prices are down -1.43% to $1.38 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The HRTX shares have gain 6.15% over the last week, with a monthly amount drifted -27.75%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Heron Therapeutics Inc [NASDAQ: HRTX] stock has seen the most recent analyst activity on June 09, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $6. Previously, Rodman & Renshaw started tracking the stock with Buy rating on June 13, 2024, and set its price target to $7. On April 23, 2024, CapitalOne initiated with a Overweight rating and assigned a price target of $6 on the stock. Needham reiterated its Buy rating and increased its price target to $5 on March 13, 2024. Guggenheim initiated its recommendation with a Buy and recommended $24 as its price target on May 27, 2020. Needham reiterated a Buy rating for this stock on February 20, 2020, and downed its price target to $48. In a note dated January 16, 2019, Needham reiterated an Buy rating on this stock and revised its target price from $66 to $64.
The stock price of Heron Therapeutics Inc [HRTX] has been fluctuating between $1.04 and $2.68 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Heron Therapeutics Inc [NASDAQ: HRTX] shares were valued at $1.38 at the most recent close of the market. An investor can expect a potential return of 334.78% based on the average HRTX price forecast.
Analyzing the HRTX fundamentals
The Heron Therapeutics Inc [NASDAQ:HRTX] reported sales of 149.69M for trailing twelve months, representing a surge of 3.26%. Gross Profit Margin for this corporation currently stands at 0.75% with Operating Profit Margin at 0.01%, Pretax Profit Margin comes in at -0.01%, and Net Profit Margin reading is -0.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.0, Equity is 0.03 and Total Capital is -0.05. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.48.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3600 points at the first support level, and at 1.3400 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.4100, and for the 2nd resistance point, it is at 1.4400.
Ratios To Look Out For
It’s worth pointing out that Heron Therapeutics Inc [NASDAQ:HRTX]’s Current Ratio is 0.82. As well, the Quick Ratio is 0.53, while the Cash Ratio is 0.06. Considering the valuation of this stock, the price to sales ratio is 1.41.
Transactions by insiders
Recent insider trading involved Rubric Capital Management LP, 10% Owner, that happened on Aug 08 ’25 when 2.39 million shares were purchased. Director, Morgan Adam completed a deal on Aug 08 ’25 to buy 1.77 million shares.
